title: Managing localized unresectable hepatocellular carcinoma.
abstract: Hepatocellular carcinoma is becoming more common, and numerous treatment algorithms are available for this complex disease. This article reviews screening, diagnosis, staging, and management of hepatocellular carcinoma, including various treatments for patients who are not candidates for surgical resection and transplantation.
authors.affiliation: Jyoti Narang-Master is chief PA for the Department of Surgery at Bellevue Hospital, affiliated with NYU Langone. Denise Rizzolo is an associate professor in the PA program at Seton Hall University in South Orange, N.J., an assistant clinical professor in the Pace completion program in New York City, and practices urgent care in Springfield, N.J. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Jyoti
authors.initials: J
authors.lastname: Narang-Master
authors.forename: Denise
authors.initials: D
authors.lastname: Rizzolo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D055088:Early Detection of Cancer; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D012307:Risk Factors; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib